Dr Reddy s Laboratories along with its subsidiaries announced the launch of Fluphenazine Hydrochloride Tablets, USP, in the U.S. market.
The company along with its subsidiaries today announced the launch of Fluphenazine Hydrochloride Tablets, USP, a therapeutic equivalent generic version of Prolixin Tablets, 1 mg, 2.5 mg, 5 mg, and 10 mg, approved by the U.S. Food and Drug Administration (USFDA).
The Prolixin brand and generic had U.S. sales of approximately $134 million MAT for the most recent twelve months ending in December 2020 according to IQVIA Health.
Dr Reddy s Fluphenazine Hydrochloride Tablets, USP are available in 1 mg, 2.5 mg, 5 mg, and 10 mg tablets in 100 bottle count sizes.
Read more about Dr Reddy s Laboratories launches cancer treatment drug Capecitabine in US on Business Standard. The product is a therapeutic equivalent generic version of Xeloda (capecitabine) tablets approved by the US Food and Drug Administration (USFDA)
Read more about Sensex extends losses amid global weakness; HDFC twins drag on Business Standard. Equity indices buckled under selling pressure for the second straight session on Wednesday as risk appetite remained subdued amid a bearish trend overseas
Synopsis
The product is a therapeutic equivalent generic version of Xeloda (capecitabine) tablets approved by the US Food and Drug Administration (USFDA).
Agencies
In a regulatory filing, Dr Reddy s laboratories announced launch of Capecitabine tablets in the US.
The product is a therapeutic equivalent generic version of Xeloda (capecitabine) tablets approved by the US Food and Drug Administration (USFDA).
In a regulatory filing, Dr Reddy s laboratories announced launch of Capecitabine tablets in the US.
Quoting IQVIA Health data, Dr Reddy s said the Xeloda brand and generic had US sales of approximately USD 90 million for the most recent 12 months ending in October 2020.
Russia s Sputnik vaccine may get emergency use authorisation in April
Premium
A shipment of doses of the Sputnik V (Gam-COVID-Vac) vaccine against the coronavirus disease (COVID-19). (FILE PHOTO: Reuters)
1 min read
Share Via
Read Full Story
NEW DELHI: Russia’s Sputnik vaccine, developed by Gamaleya Research Institute of Epidemiology and Microbiology, to combat covid-19 may get emergency use authorisation in April, two people familiar with the matter said on Tuesday.
News reports on Monday had said that the Russian vaccine can get clearance for use as early as next month.
TRENDING STORIESSee All
1 min read
1 min read
2 min read
2 min read